NCT05490472View on ClinicalTrials.gov

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2026

Conditions
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBCARID1A Gene MutationSmall Cell Lung Cancer, SCLC
Interventions
DRUG

JAB-2485 (Aurora A inhibitor)

Administered orally

DRUG

JAB-2485 (Aurora A inhibitor)

Administered orally

Trial Locations (5)

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

84112

RECRUITING

University of Utah Huntsman Cancer Institute, Salt Lake City

100101

NOT_YET_RECRUITING

Research site02, Beijing

130000

NOT_YET_RECRUITING

Research site01, Changchun

250117

NOT_YET_RECRUITING

Research site03, Jinan

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05490472 - JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter